Guest post: Good news for the SFO in Innospec – jury convicts former CEO and sales director

Dennis Kerrison and Miltiades Papachristos were found guilty [on Wednesday 18 June] at Southwark Crown Court of conspiracy to commit corruption. In a nutshell, that they gave or agreed to give corrupt payments to public officials and other agents of the Government of Indonesia as inducements to secure, or as rewards for having secured, contracts from the Government of Indonesia for the supply of fuel manufactured by Innospec. Continue reading “Guest post: Good news for the SFO in Innospec – jury convicts former CEO and sales director”

Guest post: Is sustainability improving corporate and professional ethics?

The ethical dimensions of in-house practice are a significant source of academic and practical interest, as the recent investigation of GM suggests. I have the pleasure of doing two projects where I engage with in-house lawyers on ethical questions: one on the ethics of legal practice and the other on legal risk. So it was with great interest that I read Bond Dickinson report Beyond Responsibility: The emerging role of legal counsel in sustainable business. Continue reading “Guest post: Is sustainability improving corporate and professional ethics?”

Guest post: Pfizer’s placebo promises (why AstraZeneca may have been right to reject the ‘final’ takeover bid from Pfizer)

In front of the Commons Business committee last week, Ian Read, chairman and chief executive of Pfizer, made two points in relation to Pfizer’s commitments, assuming it were to succeed in acquiring the Anglo-Swedish drug manufacturer AstraZeneca. Continue reading “Guest post: Pfizer’s placebo promises (why AstraZeneca may have been right to reject the ‘final’ takeover bid from Pfizer)”

Guest post: Pfizer’s bid for AstraZeneca – what can the government do?

On April 28, Pfizer announced a possible offer to buy AstraZeneca, presumably having thought an announcement was required by rule 2.2 of the Takeover Code. The result is that, under the relatively new ‘put up or shut up’ rule now embodied in rule 2.5 of the Code, Pfizer has until 5 o’clock on May 26 – the 28th day after its announcement – in which to make a firm offer.

Continue reading “Guest post: Pfizer’s bid for AstraZeneca – what can the government do?”